56S0 Stock Overview

Engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. More details

56S0 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	4/6
Past Performance	1/6
Financial Health	2/6
Dividends	0/6

Rewards

Earnings are forecast to grow 31.96% per year

Risk Analysis

Interest payments are not well covered by earnings

Profit margins (5.9%) are lower than last year (15.6%)

Shareholders have been diluted in the past year

Large one-off items impacting financial results

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Sartorius Stedim Biotech S.A. Competitors

SCHOTT Pharma KGaA

XTRA:1SXP

€3.6b

Gerresheimer

XTRA:GXI

€2.6b

Merck KGaA

XTRA:MRK

€61.3b

Divi's Laboratories

NSEI:DIVISLAB

₹1.6t

Price History & Performance

Summary of share price highs, lows and changes for Sartorius Stedim Biotech
Historical stock prices
Current Share Price	€18.20
52 Week High	€28.20
52 Week Low	€14.00
Beta	0.67
1 Month Change	9.64%
3 Month Change	5.20%
1 Year Change	-20.87%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-43.83%

Recent updates

Shareholder Returns

	56S0	DE Life Sciences	DE Market
7D	-2.2%	-0.7%	-1.4%
1Y	-20.9%	-3.9%	8.0%

Return vs Industry: 56S0 underperformed the German Life Sciences industry which returned -3.9% over the past year.

Return vs Market: 56S0 underperformed the German Market which returned 8.1% over the past year.

Price Volatility

Is 56S0's price volatile compared to industry and market?
56S0 volatility
56S0 Average Weekly Movement	7.8%
Life Sciences Industry Average Movement	7.2%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.9%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: 56S0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 56S0's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1978	10,082	Rene Faber	www.sartorius.com

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products.

Sartorius Stedim Biotech S.A. Fundamentals Summary

How do Sartorius Stedim Biotech's earnings and revenue compare to its market cap?
56S0 fundamental statistics
Market cap	€18.32b
Earnings (TTM)	€160.60m
Revenue (TTM)	€2.74b

114.1x

P/E Ratio

6.7x

P/S Ratio

Is 56S0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
56S0 income statement (TTM)
Revenue	€2.74b
Cost of Revenue	€1.55b
Gross Profit	€1.19b
Other Expenses	€1.02b
Earnings	€160.60m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 28, 2025

Earnings per share (EPS)	1.65
Gross Margin	43.33%
Net Profit Margin	5.87%
Debt/Equity Ratio	68.4%

How did 56S0 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

38%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/18 15:58
End of Day Share Price	2024/12/18 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sartorius Stedim Biotech S.A. is covered by 31 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Stéphan Dubosq	Arkeon Finance
Charles Pitman-King	Barclays
Scott Bardo	Berenberg